SRPT Sarepta Therapeutics Inc.

122.99
-4.91  -4%
Previous Close 127.9
Open 127.49
Price To Book 9.21
Market Cap 9,168,058,698
Shares 74,543,123
Volume 1,489,456
Short Ratio
Av. Daily Volume 1,450,461
Stock charts supplied by TradingView

NewsSee all news

  1. Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

    CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its

  2. Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th

  3. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019, that were previously

  4. Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

    – Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in cash and $400

  5. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta's investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At closing, Roche will pay

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling NDA commenced January 2020.
Casimersen
Duchenne muscular dystrophy
Phase 1/2 ongoing.
rAAVrh74.MCK.GALGT2
Duchenne muscular dystrophy
Aims to have dosing and safety insight by mid-2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
FDA Approval announced December 12, 2019.
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete.
MYO-102
Duchenne muscular dystrophy - LGMD2D
Read out of high-dose cohort and select dose 2Q 2020.
MYO-101 (SRP-9003)
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019. Dosing to be completed 1H 2020.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)
Phase 2 expression and functional read out due early 2021.
SRP-9001
Duchenne muscular dystrophy

Latest News

  1. Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

    CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its

  2. Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th

  3. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019, that were previously

  4. Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

    – Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in cash and $400

  5. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta's investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At closing, Roche will pay

  6. Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds

  7. Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

    -- VYONDYS 53 is Sarepta's second RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately -- -- Information for patients and clinicians

  8. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019, that were previously

  9. Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

    -- Agreement leverages StrideBio's novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta's early stage gene therapy pipeline – -- Sarepta granted an exclusive license to four CNS

  10. Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019.

  11. Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference

    CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the

  12. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2019, that were previously

  13. Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019

    CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2019 financial results after the

  14. Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    -- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data

  15. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were

  16. Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4, 2019 at 8:00 a.m.

  17. CLASS ACTION UPDATE for CTST, JE, VAL and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  18. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) ("Sarepta" or the "Company") of

  19. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MMM, GTT, PS and SRPT

    CEDARHURST, N.Y., Sept. 06, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies.

  20. IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  21. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 5, 2019) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)("Sarepta" or the "Company")

  22. IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  23. Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne

  24. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) in the

  25. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the

  26. CLASS ACTION UPDATE for JE, TWOU, EVH and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  27. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the October

  28. SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta"

  29. Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the

  30. INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc.

    --(BUSINESS WIRE)--The law firm of

  31. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019, that were previously

  32. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT).   Such investors are advised to

  33. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sarepta Therapeutics, Inc.

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta or "the Company") (NASDAQ:SRPT) concerning possible